Prev Close | 136.47 |
Open | 137.34 |
Day Low/High | 135.71 / 138.03 |
52 Wk Low/High | 105.43 / 192.79 |
Volume | 344.94K |
Prev Close | 136.47 |
Open | 137.34 |
Day Low/High | 135.71 / 138.03 |
52 Wk Low/High | 105.43 / 192.79 |
Volume | 344.94K |
Exchange | NASDAQ |
Shares Outstanding | 184.08B |
Market Cap | 24.57B |
P/E Ratio | 69.22 |
Div & Yield | N.A. (N.A) |
A HERO may still emerge.
Become more aggressive about the real valuations of companies.
The $193 level on the SPY will be key today.
Thursday's SPY trade plan will involve fading the edges,
You're looking at one.
TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.
For these kinds of growth stocks, you have no choice but to wait.
Here are some specific stocks working as parables right now.
It's sardonic, corroded commentary designed to keep your pole in the boat.
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
Here is my compilation of last night's profit reports. 24 beats: W&T Offshore (WTI) Oasis Petroleum (OAS) Marathon Oil (MRO) Huntington Ingalls Industries (HII) Cognizant Technology Solutions (CTSH) Disney (DIS) Electronic Arts (EA) Regency Centers ...
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.